IREN Limited (IREN) is reiterated as a 'Strong Buy' after a 17% dip, with fundamentals and AI-driven growth intact. Management targets $3.4 billion in annualized AI cloud revenue by end-2026, supported by multi-year contracts including Microsoft. IREN trades at a forward P/S below 5 and FY2028 P/E of 16, with net cash and strong profitability, making valuation highly attractive.

New eSignature features bring clarity for signers and efficiency gains for businesses SAN FRANCISCO, Jan. 13, 2026 /PRNewswire/ -- Docusign (NASDAQ: DOCU) today announced new AI-powered eSignature features that make agreements easier to understand for signers and dramatically faster to prepare for businesses. Powered by the Docusign Intelligent Agreement Management (IAM) platform, the new experiences tackle two persistent challenges in the agreement process: dense legal language that slows signers down and the manual, error-prone work of document preparation that takes valuable time away from teams.

Sales edged down to 737,000 in October last year, from 738,000 in September, but up from a downwardly revised 711,000 in August.

While other burger brands are cutting the bun, Portillo's is offering a (b)unbelievable deal celebrating its fan-favorite char-broiled burgers While other burger brands are cutting the bun, Portillo's is offering a (b)unbelievable deal celebrating its fan-favorite char-broiled burgers

Micron Technology (MU) remains a 'Buy' for 2026, driven by strong AI-related memory demand and current pricing power. MU faces three key risks: cyclical valuation, potential oversupply and approaching peak margins in 2026–2027. Samsung's advances in HBM4 and aggressive pricing could accelerate a memory market oversupply, impacting MU's margins and profitability.

A Defense Department agreement derisked MP's growth plans and lifted analyst price targets.

Boston, Massachusetts--(Newsfile Corp. - January 13, 2026) - Block & Leviton is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) for potential securities law violations. Investors who have lost money in their Aquestive Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.

Jim Cramer, a former hedge fund manager and the face of CNBC's Mad Money, continues to keep faith with Boeing (NYSE: BA), calling it ‘the stock he most wanted to own' coming into 2026.

LOS ANGELES, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Integer Holdings Corporation (“Integer” or “the Company”) (NYSE: ITGR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 25, 2024 and October 22, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before February 9, 2026.

TSN's chicken unit has delivered strong margin gains and profit growth in fiscal 2025, but sustaining momentum hinges on execution and cost discipline.

Intrepid Potash reports successful tests turning byproduct brine into battery-grade lithium carbonate at its Utah facility, advancing a joint lithium project.

The consensus price target hints at a 40.4% upside potential for Quantum Computing Inc. (QUBT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

From a technical perspective, Plains All American Pipeline, L.P. (PAA) is looking like an interesting pick, as it just reached a key level of support.

The average of price targets set by Wall Street analysts indicates a potential upside of 32.5% in Freightcar America (RAIL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in West Pharmaceutical (WST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 27.3% in SEI (SEIC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

After losing some value lately, a hammer chart pattern has been formed for Vanda (VNDA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

The Bank of New York Mellon Corporation has delivered strong performance, with shares up over 50% in the past year and Q4 earnings beating estimates. BK's industry-leading cost efficiency drove margin expansion, but the pace of further improvement is expected to slow as easy cost cuts are exhausted. Revenue growth guidance of 5% and continued capital returns are supported by a robust balance sheet, yet valuation now fully reflects these positives.

GM's NEV sales in China near 1M units in 2025, topping half of deliveries as market share, joint-venture volumes, and new launches hit records.

PATH's rebound signals rising confidence as improving fundamentals, attractive valuation and AI automation progress lift the long-term outlook.